XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Revenue:        
Total revenue $ 130,164 $ 114,428 $ 244,637 $ 211,272
Cost of revenue:        
Intangible asset amortization - cost of revenue 2,667 2,909 5,252 5,824
Total cost of revenue 40,395 36,515 75,360 70,891
Gross profit 89,769 77,913 169,277 140,381
Operating expenses:        
Research and development 16,264 16,465 33,984 32,430
Selling and marketing 25,316 24,216 49,770 47,998
General and administrative 32,331 31,745 66,139 57,955
Impairment of assets 20,505 0 20,505 429
Total operating expenses 95,037 73,307 171,641 140,431
Income (loss) from operations (5,268) 4,606 (2,364) (50)
Other income, net 6,518 2,755 11,042 5,503
Income (loss) before income taxes 1,250 7,361 8,678 5,453
Income tax provision 2,230 1,627 2,611 1,583
Net income (loss) $ (980) $ 5,734 $ 6,067 $ 3,870
Earnings (loss) per share:        
Basic (in USD per share) $ (0.01) $ 0.07 $ 0.08 $ 0.05
Diluted (in USD per share) $ (0.01) $ 0.07 $ 0.08 $ 0.05
Shares used to compute earnings (loss) per common share:        
Basic (in shares) 78,391,502 76,538,325 78,210,881 75,649,057
Diluted (in shares) 78,391,502 77,163,149 79,905,121 76,600,079
Testing revenue        
Revenue:        
Total revenue $ 122,263 $ 106,970 $ 229,572 $ 197,273
Cost of revenue:        
Cost of revenue 32,407 27,920 60,667 53,899
Product revenue        
Revenue:        
Total revenue 3,598 3,906 7,178 7,443
Cost of revenue:        
Cost of revenue 1,749 1,874 3,171 4,518
Biopharmaceutical and other revenue        
Revenue:        
Total revenue 4,303 3,552 7,887 6,556
Cost of revenue:        
Cost of revenue 3,572 3,812 6,270 6,650
Intangible Asset Amortization        
Operating expenses:        
Intangible asset amortization - operating expenses $ 621 $ 881 $ 1,243 $ 1,619